Fig. 4: Monocyte population displays epichaperome abundance and immunophenotyped changes during the course of treatment with PU-H71 while T lymphocytes are not affected. | npj Precision Oncology

Fig. 4: Monocyte population displays epichaperome abundance and immunophenotyped changes during the course of treatment with PU-H71 while T lymphocytes are not affected.

From: Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia

Fig. 4: Monocyte population displays epichaperome abundance and immunophenotyped changes during the course of treatment with PU-H71 while T lymphocytes are not affected.

a Epichaperome abundance in monocytes and CD3 + T-cell lymphocytes in WCM254 compared with normal PB lymphocytes (NPB). Graph, mean ± SD of MFI of monocytes/MFI of CD3 + lymphocytes. b Representative monocyte subsets (classical, intermediate, and non-classical) based on CD14 and CD16 expression in normal healthy donor (left). Chronological changes in monocyte subsets in patient WCM254 during PU-H71 therapy (right). Pro-inflammatory subsets CD14highCD16 + (intermediate) and CD14lowCD16 + (non-classical) decreased after PU-H71 treatment reflecting proportions similar to normal monocyte subsets. c Phenotyping of T-lymphocytes in WCM254 at baseline, day 25 and day 32, with representative T cells from a healthy donor shown on the left. Proportion of CD4 + and CD8 + T lymphocytes and naive/central memory/effector/terminally differentiated effector T cells of each CD4 + and CD8 + T cells did not show changes in WCM254 under PU-H71 treatment (right three columns).

Back to article page